Be Visible
  • Home
  • Navigate
    • About Us
    • Discover a new cause
    • Merch
    • Donate
  • More
    • Home
    • Navigate
      • About Us
      • Discover a new cause
      • Merch
      • Donate
Be Visible
Discover a New Cause
  • Home
  • Navigate
    • About Us
    • Discover a new cause
    • Merch
    • Donate
Discover a New Cause

Understanding the Rare Journey

A rare diagnosis often leaves families navigating the unknown, facing challenges that few people—and even fewer medical resources—are fully equipped to address. While each rare condition has its own distinct genetic blueprint, the hurdles families experience are deeply shared: the quest for clear answers, the fight against isolation, and the urgent need for therapeutic breakthroughs.


Be Visible was born from our direct journey with STXBP1, which serves as our home base and primary catalyst for action.


At the same time, we believe that bringing visibility to one condition helps illuminate them all. By highlighting STXBP1 alongside other rare disorders, our goal is to elevate the broader rare disease conversation, break down systemic barriers to care, and amplify the work of dedicated patient communities everywhere.


Explore the conditions below to learn more about the science, the shared challenges, and the incredible organizations leading the charge toward hope and cures.







Rare Disease Hub

STXBP1 Disorder

Angelman Syndrome (UBE3A)

Spinal Muscular Atrophy

  • Core Impact: Disrupts neurotransmitter release in the brain, resulting in global developmental delays, severe speech and communication barriers, movement disorders, and low muscle tone.
  • Path to a Cure: Active translational research in disease-modifying small-molecule chaperones, antisense oligonucleotides (ASOs), and targeted gene therapy strategies aimed at restoring STXBP1 protein levels and synaptic function.

Learn more

Spinal Muscular Atrophy

Angelman Syndrome (UBE3A)

Spinal Muscular Atrophy

  • Core Impact: Causes progressive motor neuron loss, leading to muscle weakness, loss of independent mobility, and severe respiratory and swallowing difficulties.
  • Path to a Cure: A landmark blueprint for rare genetic diseases, with proven, disease-modifying targeted therapies already established (AAV9 gene replacement and RNA splicing modulators) alongside ongoing next-generation genetic therapies.

Learn more

Angelman Syndrome (UBE3A)

Angelman Syndrome (UBE3A)

Angelman Syndrome (UBE3A)

  • Core Impact: A neurogenetic disorder resulting in severe speech impairment, motor and balance instability (ataxia), intellectual disability, and profound sleep disturbances.
  • Path to a Cure: High-potential pipeline focused on un-silencing the dormant paternal UBE3A gene copy in neurons using ASOs, CRISPR activation, and viral vector-delivered gene therapy currently in active clinical trials.

Learn more

Sanfilippo Syndrome

Duchenne Muscular Dystrophy (DMD)

Sanfilippo Syndrome

  • Core Impact: A rare lysosomal storage disease causing toxic substrate accumulation in the central nervous system, leading to childhood neurocognitive decline, loss of speech and motor skills, and hyperactivity.
  • Path to a Cure: Clinical-stage gene therapies (AAV vectors targeting the brain), enzyme replacement therapies, and substrate reduction approaches actively working to halt neurodegeneration.

Learn more

Friedreich’s Ataxia

Duchenne Muscular Dystrophy (DMD)

Sanfilippo Syndrome

  • Core Impact: A genetic neurodegenerative disorder caused by GAA repeat expansions, resulting in progressive loss of physical coordination, muscle weakness, severe fatigue, and hypertrophic cardiomyopathy.
  • Path to a Cure: Active development of frataxin-restoring gene therapy, synthetic transcription factors to reactivate FXN transcription, and mitochondrial targeted therapeutics.

Learn more

Duchenne Muscular Dystrophy (DMD)

Duchenne Muscular Dystrophy (DMD)

Duchenne Muscular Dystrophy (DMD)

  • Core Impact: A severe genetic condition causing progressive muscle degeneration and weakness, loss of ambulation in early adolescence, and eventual cardiac/respiratory complications.
  • Path to a Cure: Established and advancing precision genetic medicine pipelines, including FDA-approved micro-dystrophin gene replacement therapies, exon-skipping ASOs, and CRISPR base-editing clinical research.

Learn more

Copyright © 2026 Be Visible - All Rights Reserved.

Powered by

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

Accept